The human body produces T cells to recognize and fight disease. Each T cell has a unique T cell receptor (or TCR) on its surface that surveils small fragments of proteins presented by other cells. Upon detecting evidence of cancer or infection, a subset of T cells binds the diseased cells and orchestrates their elimination. When tumors and infections cannot be eradicated naturally, researchers employ immunotherapies to boost the immune system’s effectiveness.
By inserting genes encoding a tumor-specific TCR into a patient’s T cells, researchers can engineer a large population of T cells to target tumor cells. This approach, called TCR gene therapy, has yielded clinical successes where conventional cancer treatments have failed. However, TCR gene therapy is not without risk. The introduced receptor can become tangled with the resident receptor in each engineered T cell, causing some of these cells to attack healthy cells. A new technique developed by Caltech researchers prevents this from happening, increasing the safety of TCR gene therapy.
Click here to Read the full article: Genetically engineering disease-fighting cells
Share this entry
- The American Health Council Welcomes Brooke Ingram, BSN, RN to its Board of Nurses March 8, 2018
- The American Health Council Selects Sally Pierre, BSN, RN to Nursing Board March 6, 2018
- The American Health Council Appoints Kristin Bouman, RN, BSN, CCRN, CPR, NRS, STABLE to Nursing Board March 2, 2018
- The American Health Council Nursing Board Welcomes April Scott, RN February 28, 2018
- American Health Council Selects Amy Neri, RN to Nursing Board February 27, 2018
- “We need to be grateful to the people who helped us get here” February 26, 2018